anti-Solute Carrier Family 5 (Sodium/glucose Cotransporter), Member 2 (SLC5A2) Antikörper

SLC5A2 encodes a member of the sodium glucose cotransporter family which are sodium-dependent glucose transport proteins. Zusätzlich bieten wir Ihnen SLC5A2 Kits (19) und SLC5A2 Proteine (9) und viele weitere Produktgruppen zu diesem Protein an.

Alle Antikörper anzeigen Gen GeneID UniProt
SLC5A2 6524 P31639
SLC5A2 246787 Q923I7
SLC5A2 64522 P53792
Direkt bei antikoerper-online bestellen
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Online bestellen
  • orders@antikoerper-online.de

Top anti-SLC5A2 Antikörper auf antikoerper-online.de

Showing 10 out of 53 products:

Katalog Nr. Reaktivität Wirt Konjugat Applikation Bilder Menge Lieferzeit Preis Details
Rind (Kuh) Kaninchen Unkonjugiert WB 100 μL 2 bis 3 Tage
$319.00
Details
Human Kaninchen Unkonjugiert WB Western blot analysis of SGLT- 2 in Jurkat cell lysate (Lane 1) and mouse small intestine tissue lysate (Lane 2). 100 μg 2 bis 3 Tage
$310.00
Details
Human Kaninchen Unkonjugiert WB Western blot analysis of SGLT2 expression in HeLa (A), SP2/0 (B), H9C2 (C) whole cell lysates. 200 μL 13 bis 14 Tage
$487.50
Details
Human Kaninchen Unkonjugiert ELISA, WB Western blot analysis of extracts from 293 cells, using SLC5A2 Antibody. The lane on the right is treated with the synthesized peptide. 100 μg 2 bis 3 Tage
$302.50
Details
Pferd Kaninchen Unkonjugiert IHC, IHC (p) Anti-SLC5A2 antibody  ABIN1049344 IHC staining of human kidney, collecting duct. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. 50 μg 11 bis 14 Tage
$484.00
Details
Human Kaninchen Unkonjugiert WB 100 μL 11 bis 14 Tage
$581.17
Details
Human Kaninchen Unkonjugiert ELISA, ICC, IF, WB Western blot analysis of extracts from 293 cells, using SLC5A2 antibody.The lane on the left is treated with the antigen-specific peptide. ABIN6275580 staining 293 by IF/ICC. The sample were fixed with PFA and permeabilized in 0.1% Triton X-100,then blocked in 10% serum for 45 minutes at 25¡ãC. The primary antibody was diluted at 1/200 and incubated with the sample for 1 hour at 37¡ãC. An  Alexa Fluor 594 conjugated goat anti-rabbit IgG (H+L) Ab, diluted at 1/600, was used as the secondary antibod 100 μL 11 bis 12 Tage
$390.77
Details
Human Kaninchen Unkonjugiert ELISA, IHC (p), WB   100 μg 4 bis 6 Tage
$280.00
Details
Human Kaninchen Unkonjugiert ELISA, WB   100 μL Verfügbar
$363.46
Details
Human Kaninchen Unkonjugiert IHC (p) 50 μg 12 bis 14 Tage
$686.14
Details

Am meisten referenzierte anti-SLC5A2 Antikörper

  1. Human Polyclonal SLC5A2 Primary Antibody für ICC, IF - ABIN4353213 : Bonner, Kerr-Conte, Gmyr, Queniat, Moerman, Thévenet, Beaucamps, Delalleau, Popescu, Malaisse, Sener, Deprez, Abderrahmani, Staels, Pattou: Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. in Nature medicine 2015 (PubMed)
    Show all 2 Pubmed References

Weitere Antikörper gegen SLC5A2 Interaktionspartner

Cow (Bovine) Solute Carrier Family 5 (Sodium/glucose Cotransporter), Member 2 (SLC5A2) Interaktionspartner

  1. cloning and distribution of SGLT2 mRNA expression in bovine tissues; SGLT2 mRNA was detected predominantly in the kidney; expression of SGLT2 mRNA in mammary gland increased more than 10-fold from late pregnancy to early lactation

Human Solute Carrier Family 5 (Sodium/glucose Cotransporter), Member 2 (SLC5A2) Interaktionspartner

  1. It suggests that the reduced expression of GLUT-1 and overexpression of SGLT-2 are associated with false-negative lymph node metastases in NSCLC.

  2. Membrane-associated protein 17 (MAP17) is shown to colocalize and coimmunoprecipitate with sodium/glucose cotransporter 2 (SGLT2).

  3. Tissue-specific nucleosome occupancy plays an important role in the regulation of SGLT2 gene expression in renal proximal tubular epithelial cells.

  4. ten novel SLC5A2 mutations and determination of the renal threshold for glucose excretion in Chinese patients with familial renal glucosuria

  5. Results show that SGLT2 is upregulated in non-small cell lung cancer (NSCLC) patient samples and cell lines. Its 3'UTR is the direct target of miR-296.

  6. SGLT1, SGLT2 and GLUT2 have roles in renal glucose handling [review]

  7. An inhibitor of the renal sodium/glucose cotransporter 2 (SGLT2), dapagliflozin, successfully prevented the development of cardiomyopathy in SKO mice. This is particularly relevant, given that SGLT2i treatment reduces cardiovascular event in T2DM patients. [review]

  8. SGLT2-I therapy is a potential new strategy for the treatment of HCC.

  9. Data suggest expression of SGLT1 is markedly increased in kidney of patients with type 2 diabetes as compared to control subjects; SGLT1 mRNA is highly and significantly correlated with fasting and postprandial plasma glucose and HbA1c. In contrast, data suggest SGLT2 and GLUT2 mRNA in kidney are down-regulated in type 2 diabetes, but not to statistically significant level. (GLUT2 = glucose transporter type 2)

  10. Data suggest that SGLT2 expression is higher in control kidney than in kidney from subjects with type 2 diabetes; SGLT1 expression in kidney tended in the same direction; SGLT2 appears to be localized to tubular brush-border membranes; unaffected renal tissues were obtained from subjects undergoing unilateral nephrectomy for renal carcinomas.

  11. Sodium-glucose cotransporter-2 (SGLT2) is selectively expressed in the human kidney, where it executes reabsorption of filtered glucose with a high capacity; it may be overactive in patients with diabetes, especially in the early, hyperfiltering stage of the disease. As a therapeutic target, SGLT2 has been successfully engaged by orally active, selective agents. [review]

  12. In this study, more than 90% of patients were on Forxiga or Invokana. Merck and Pfizer are also collaborating to bring an SGLT2 rival drug, ertugliflozin, to market as well as on two combinations containing the drug to treat type 2 diabetes.

  13. Canagliflozin, an orally active inhibitor of sodium glucose co-transporter 2, is approved for the treatment of type-2 diabetes mellitus. Food did not affect canagliflozin pharmacokinetics.

  14. C-peptide-based measurements of insulin secretion are appropriate for assessing beta-cell function in SGLT2 inhibitor canagliflozin-treated participants.

  15. The novel pathogenic SLC5A2 mutation p.S293C was responsible for the onset of FRG

  16. Molecular Interaction of Anti-Diabetic Drugs With Acetylcholinesterase and Sodium Glucose Co-Transporter 2.

  17. the key pharmacodynamic effects of SGLT2 inhibitors and the clinical evidence that support the rationale for the use of SGLT2 inhibitors in patients with HF who have T2D. Because these favorable effects presumably occur independent of blood glucose lowering, we also explore the potential use of SGLT2 inhibition in patients without T2D with HF or at risk of HF, such as in patients with coronary artery disease

  18. Results provide evidence that common genetic variants in the SLC5A2 gene do not affect diabetes-related metabolic traits in subjects at increased risk of type 2 diabetes.

  19. SGLT2/MAP17 functions as a low-affinity Na(+)-glucose cotransporter in the kidney.

  20. reported nominal effects of individual SLC5A2 variants on fasting and post-challenge glucose levels may probably not be mediated by altered glucagon release

Mouse (Murine) Solute Carrier Family 5 (Sodium/glucose Cotransporter), Member 2 (SLC5A2) Interaktionspartner

  1. An inhibitor of the renal sodium/glucose cotransporter 2 (SGLT2), dapagliflozin, successfully prevented the development of cardiomyopathy in SKO mice. This is particularly relevant, given that SGLT2i treatment reduces cardiovascular event in T2DM patients. [review]

  2. By studying glucagon secretion in cultured alpha cells, a role was revealed for SGLT1 in modulating the promoter effect of Dapagliflozin (a highly selective SGLT2 inhibitor) on glucagon release.

  3. SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Effects are augmentated of the by DPP4 inhibitor Saxagliptin.

  4. Taken together, it was concluded that the effect of SGLT2 inhibition on weight loss is in part mediated via the liver-brain-adipose neurocircuitry.

  5. Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppress albuminuria and tubulointerstitial injury in obese and type 2 diabetic mice. Inhibition of glucose entry into tubular cells by tofogliflozin may exert renoprotective properties in diabetes.

  6. SGLT2 inhibition induced gluconeogenesis mainly in the kidney, whereas for low carbohydrate diet, it was predominantly in the liver.

  7. Suggest SGLT2 inhibitor pragliflozin may be effective when administered as part of a combination regimen in the treatment of type 2 diabetes.

  8. these results suggest that SGLT2i treatment acutely suppresses energy expenditure in BAT via regulation of an inter-organ neural network consisting of the common hepatic vagal branch and sympathetic nerves.

  9. In conclusion, SGLT2 inhibitor luseogliflozin ameliorates glycemic control and thus exerts protective effects on pancreatic beta-cell mass and function.

  10. SGLT2 can transport gentamicin and contribute to gentamicin-induced cytotoxicity.

  11. SGLT2 is inhibited with dapagliflozin in pancreatic alpha cells, which triggers glucagon secretion

  12. DNA sequencing of SGLT2 in SAMP10/TaSlc mice revealed a single nucleotide deletion of guanine at 1236, which resulted in a frameshift mutation that produced a truncated protein.

  13. Improved glycemic control in mice lacking Sglt1 and Sglt2.

  14. Prevention of renal glucose reabsorption by SGLT2 deletion reduced hyperglycemia, improved glucose intolerance, and increased glucose-stimulated insulin secretion in vivo.

  15. SGLT2 mediates glucose reabsorption in the early proximal tubule and most of the glucose reabsorption by the kidney, overall.

SLC5A2 Antigen-Profil

Protein Überblick

This gene encodes a member of the sodium glucose cotransporter family which are sodium-dependent glucose transport proteins. The encoded protein is the major cotransporter involved in glucose reabsorption in the kidney. Mutations in this gene are associated with renal glucosuria.

Genbezeichner und Symbole assoziert mit SLC5A2

  • solute carrier family 5 member 2 (SLC5A2) Antikörper
  • solute carrier family 5 member 2 (slc5a2) Antikörper
  • solute carrier family 5 (sodium/glucose cotransporter), member 2 (slc5a2) Antikörper
  • solute carrier family 5 (sodium/glucose cotransporter), member 2 L homeolog (slc5a2.L) Antikörper
  • solute carrier family 5 (sodium/glucose cotransporter), member 2 (Slc5a2) Antikörper
  • solute carrier family 5 member 2 (Slc5a2) Antikörper
  • DKFZp469E0433 Antikörper
  • MGC83377 Antikörper
  • Sglt2 Antikörper
  • slc5a2 Antikörper
  • zgc:85792 Antikörper

Bezeichner auf Proteinebene für SLC5A2

sodium/glucose cotransporter 2 , solute carrier family 5 (sodium/glucose cotransporter), member 2 , Na(+)/glucose cotransporter 2 , low affinity sodium-glucose cotransporter , solute carrier family 5 (sodium/glucose transporter), member 2 , solute carrier family 5 member 2 , low affinity sodium-dependent glucose cotransporter , low affinity Na-dependent glucose transporter (SGLT2) , Na(+)/nucleoside cotransporter , Na+/nucleoside cotransporter , sodium/nucleoside cotransporter

GENE ID SPEZIES
399680 Bos taurus
714228 Macaca mulatta
100136139 Oncorhynchus mykiss
100172191 Pongo abelii
405862 Danio rerio
447523 Xenopus laevis
100380144 Xenopus (Silurana) tropicalis
6524 Homo sapiens
246787 Mus musculus
64522 Rattus norvegicus
100009386 Oryctolagus cuniculus
Ausgewählte Anbieter für anti-SLC5A2 (SLC5A2) Antikörper
Haben Sie etwas anderes gesucht?